Oppenheimer & CO Inc Biomea Fusion, Inc. Transaction History
Oppenheimer & CO Inc
- $6.52 Billion
- Q4 2024
A detailed history of Oppenheimer & CO Inc transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 87,358 shares of BMEA stock, worth $302,258. This represents 0.01% of its overall portfolio holdings.
Number of Shares
87,358
Previous 87,569
0.24%
Holding current value
$302,258
Previous $884,000
61.76%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding BMEA
# of Institutions
126Shares Held
17.5MCall Options Held
1.8MPut Options Held
1.08M-
Cormorant Asset Management, LP Boston, MA3.57MShares$12.4 Million1.09% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$8.11 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.45MShares$5.02 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$4.85 Million0.0% of portfolio
-
Aisling Capital Management LP New York, NY799KShares$2.76 Million1.14% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $101M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...